All articles tagged with #antiviral therapy
Researchers have discovered that herpes simplex virus-1 (HSV-1) hijacks the 3D structure of human DNA to facilitate its replication, but blocking a key enzyme, topoisomerase I, can prevent the virus from replicating, offering a promising new target for antiviral treatments.
Paxlovid, a combination of nirmatrelvir and ritonavir, can reduce the risk of severe COVID-19 symptoms and hospitalizations, but only 15% of eligible individuals have taken it. It should be started within the first five days of symptoms and is for high-risk patients aged 12 and older. Some doctors may not prescribe it due to shortages, unfamiliarity, and concerns about drug interactions. Side effects include temporary nausea and altered taste, and there's conflicting evidence on its effect on long COVID. It's important to consult a healthcare provider if considering Paxlovid and to continue preventive measures such as handwashing and vaccination.
Pfizer has announced that the price of its antiviral therapy, Paxlovid, used to prevent severe COVID-19 symptoms, will more than double to $1,390 for a five-day course, compared to the $529 previously paid by the federal government. The price increase comes as the medication transitions to the commercial market. Pfizer stated that the pricing is based on the value it provides in reducing hospitalizations and deaths. The company also plans to offer copay programs and patient assistance programs to ensure access to the medication. The transition to the commercial market is set to begin in November 2023.